Tracking of Lipid Lowering Therapy in Jordan

Tracking Lipid-Lowering Therapy Over One Year in Middle Eastern Patients With ASCVD. The Jordan LLA Tracking Study

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05629767

Acronym

JoLLA

Enrollment

1000

Registered

2022-11-29

Start date

2022-12-11

Completion date

2024-01-02

Last updated

2024-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic Cardiovascular Disease, Dyslipidemias

Keywords

Low-density lipoprotein cholesterol (LDL-C), Target levels

Brief summary

The present study aims to examine the clinical practice of modifying the dose of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD), who have LDL-C \> 70 mg/dl despite statin treatment.

Detailed description

ASCVD is the leading cause of morbidity and mortality worldwide, in the Middle East and in Jordan. One of the major risk factors that contribute to the development and progression of ASCAD is dyslipidemia. A large number of clinical trials have reported the benefits of lowering LDL-C, in reducing the mortality rate among ASCAD patients. The 2019 ACC/AHA blood cholesterol treatment guideline to reduce atherosclerotic cardiovascular risk in adults has expanded the role of LDL-C targets and reiterated the importance of achieving an LDL-C level of 70 mg/dl or less for patients who have ASCVD. Patients on statins and other lipid-lowering therapy in Jordan have not been tracked in the past for the potential of up escalating the lipid-lowering therapy to reach the LDL-C target. The investigation will enroll patients with ASCVD who have LAL-C \>70 mg/dl on lipid-lowering therapy and follow them for 12 months to examine the treating physicians' action in up-titrating the lipid-lowering therapy dose(s) and the frequency of measuring serum lipids during the study period.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Adults aged 18 years or old. 2. Presence of atherosclerotic cardiovascular disease on lipid-lowering therapy. 3. LDL-C \> 70mg/dl. 4. Willingness to sign an informed consent.

Exclusion criteria

1. Life-threatening disease with limited survival. 2. Unwillingness to sign an informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Achieving a target LDL-C bloob level of 70 mg/dl or less	12 months	At 1 year of follow up, all participants will have their blood lipid profile measured to examine the frequency of attaining an LDL-C level of 70 mg/dl or less
Modifying the dose and class of lipid-lowering therapy	12 months	Up titrating the dose of the same lipid-lowering agent or adding new agent during the study period of 12 months. Agents available include statins, ezetimibe and PCSK9 inhibitors.
Clinical cardiovascular events	12 months	The study will study the frequency of incident acute cardiovascular the participating individuals experienced. Such events include cardiovascular death, acute coronary syndrome, stroke, lower extremity acute arterial insufficiency, and arterial revascularization procedure (coronary and other arterial beds).

Countries

Jordan

Outcome results